Teva Pharmaceutical Industries Ltd
featured
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
» Read More
.160x105.jpg?v=1366904651 "Fed Could Give Market a Safety Net")
More
-
WASHINGTON, March 29- Biogen Idec Inc said on Friday it will charge $54,900 a year for its multiple sclerosis drug, Tecfidera, which received U.S. approval on Wednesday. The company has priced the drug at a discount to key competitors such as Novartis AG's MS pill Gilenya, which costs roughly $60,000 a year, in a bid to maximize its market share.
-
*Sales of Tecfidera expected to top $3 billion by 2017. WASHINGTON, March 27- U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales topping $3 billion.
-
*Sales of Tecfidera expected to top $3 billion by 2017. March 27- U.S. regulators have approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales of more than $3 billion.
-
Spending on drugs to treat common diseases fell 1.5 percent among customers who receive prescription benefits through commercial insurers.
-
March 5- U.S. regulators granted Pfizer Inc a reissued patent on its multibillion-dollar Celebrex pain drug that extends its marketing exclusivity until early December 2015, the company said on Tuesday.
-
Feb 12- A U.S. federal court has invalidated the patent on Bristol-Myers Squibb Co's Baraclude treatment for hepatitis B after a challenge from generic drugmaker Teva Pharmaceutical Industries Ltd, Bristol-Myers said on Tuesday. " She said the company is considering whether to appeal the ruling by the U.S. District Court in Delaware.
-
Feb 12- A U.S. federal court has invalidated the patent on Bristol-Myers Squibb Co's Baraclude treatment for hepatitis B after a challenge from generic drugmaker Teva Pharmaceutical Industries Ltd, Bristol-Myers said on Tuesday. "We are disappointed with the court's decision and believe it is incorrect," Bristol-Myers spokeswoman Laura Hortas said.
-
BOSTON, Feb 6- Biogen Idec Inc's agreement to buy Elan Corp Plc's interest in the multiple sclerosis drug Tysabri gives Biogen full control of a product that is poised for further growth and ends a long partnership that has often been contentious.
-
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
-
Asian shares were mixed on Friday with a pick-up in China's manufacturing sector lending support but worries over the progress of U.S. budget talks to avert the "fiscal cliff" weighing on investor sentiment.
-
NEW YORK, Dec 11- Teva Pharmaceutical Industries' new Chief Executive Jeremy Levin promised on Tuesday to reshape the company into "the most indispensable medicines company in the world" and to provide significant value to its shareholders along the way.
-
NEW YORK, Dec 11- Teva Pharmaceutical Industries' new Chief Executive Jeremy Levin promised on Tuesday to reshape the company into "the most indispensable medicines company in the world" and to provide significant value to its shareholders along the way.
-
*Teva meeting with investors, analysts Dec. 11 in New York. NEW YORK/ TEL AVIV, Dec 5- Teva Pharmaceutical Industries' new Chief Executive Jeremy Levin has promised investors it will be a very different company going forward.
-
Nov 30- Teva Pharmaceutical Industries Ltd, the world's biggest maker of generic drugs, announced an ambitious plan to reshape the company on Friday aimed at streamlining operations, cutting costs and improving profitability.
-
Nov 30- Teva Pharmaceutical Industries Ltd, the world's biggest maker of generic drugs, forecast profit and revenue for calendar 2013 that fell short of analysts' estimates.
-
*To outline its plans in detail on Dec. 11. Nov 30- Teva Pharmaceutical Industries Ltd, the world's biggest maker of generic drugs, announced an ambitious plan on Friday to reshape the company as it faces increased competition for its top-selling multiple sclerosis drug Copaxone.
-
The Tel Aviv Stock Exchange often moves in the same direction as U.S. markets. While this has been a tough week for the bulls in the U.S. it’s been even more difficult in Israel because of the new round of violence plaguing the area.
-
*DOJ, SEC convinced enforcement changing corporate culture. At least eight of the world's top 10 drugmakers, including Bristol-Myers Squibb Co, Pfizer Inc and Johnson&, have disclosed U.S. probes under the 1977 Foreign Corrupt Practices Act.
-
Oct 26- The U.S. Food and Drug Administration on Friday said it has approved a new leukemia treatment from Teva Pharmaceutical Industries Ltd to be sold under the brand name Synribo.
